Galapagos : Une fin d’année marquée par la sortie de Jyseleca, arrêt de son CAR-T CD19 dans le rSLE
>Un contrôle des coûts déjà mis en place - Galapagos publiait après la fermeture du marché US ses résultats annuels. Après la vente effective de Jyseleca à Alfasigma en janvier dernier, la publication n’est pas si limpide entre les activités consolidées et les opérations arrêtées. Les revenus du groupe ressortent ainsi à 783.5 M€ vs 545 M€ att en incluant notamment 112 M€ de Jyseleca. L'activité de Jyseleca a contribué positivement au résultat net, avec un bénéfice n...Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.